Kodiak Sciences Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kodiak Sciences Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C2812
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kodiak Sciences Inc (Kodiak Sciences), formerly Oligasis LLC is a drug development company that discovers new medicines for the healthcare sector. The company provides retinal medicines for treatment of wet and dry forms of age-related macular degeneration. It utilizes proprietary Bioconjugate technology, which is a proprietary product platform that combines biologics design with next generation phosphorylcholine biopolymers. The company offers KSI 301 an anti-VEGF biologic development, which offers potential for patients to remain on mechanism for a longer interval between consecutive intravitreal injections. It commercializes technology to both biopharmaceuticals and small molecules companies. Kodiak Sciences is headquartered in Palo Alto, California, the US.

Kodiak Sciences Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kodiak Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Kodiak Sciences Raises USD34 Million in Series B Financing 10
Kodiak Sciences Raises USD34 Million in Venture Financing 11
Partnerships 12
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 12
Lonza Enters into Agreement with Kodiak Sciences 13
Debt Offering 14
Kodiak Sciences Raises USD33 Million in Private Placement of Notes 14
Kodiak Sciences Inc – Key Competitors 15
Kodiak Sciences Inc – Key Employees 16
Kodiak Sciences Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Jul 18, 2018: Kodiak Sciences names Bassil I. Dahiyat, Robert A. Profusek and Richard S. Levy as board directors 18
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Key Facts 2
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kodiak Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kodiak Sciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kodiak Sciences Raises USD34 Million in Series B Financing 10
Kodiak Sciences Raises USD34 Million in Venture Financing 11
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 12
Lonza Enters into Agreement with Kodiak Sciences 13
Kodiak Sciences Raises USD33 Million in Private Placement of Notes 14
Kodiak Sciences Inc, Key Competitors 15
Kodiak Sciences Inc, Key Employees 16

List of Figures
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Kodiak Sciences Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • H&R GmbH & Co KGaA (2HR):企業の財務・戦略的SWOT分析
    H&R GmbH & Co KGaA (2HR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • G4S plc:企業のM&A・事業提携・投資動向
    G4S plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's G4S plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Instrumentation Laboratory Co:企業の戦略的SWOT分析
    Instrumentation Laboratory Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Samart Corporation Plc (SAMART):企業の財務・戦略的SWOT分析
    Samart Corporation Plc (SAMART) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Pharnext SA (ALPHA):製薬・医療:M&Aディール及び事業提携情報
    Summary Pharnext SA (Pharnext), formerly Pharnext SAS is a biopharmaceutical company that develops novel therapies for severe neurodegenerative diseases. The company offers pleotherapy, a proprietary research and development platform based on network pharmacology that uses wide genomic data to ident …
  • Sociedad General de Aguas de Barcelona SA:企業の戦略的SWOT分析
    Sociedad General de Aguas de Barcelona SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Hon Hai Precision Industry Co Ltd (2317):企業の財務・戦略的SWOT分析
    Hon Hai Precision Industry Co Ltd (2317) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Laricina Energy Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Laricina Energy Ltd (Laricina Energy) is an upstream oil and gas company that explores, produces and develops oil sand properties in Western Canada. The company offers development of underground bitumen deposits in sand and carbonate formations. It operates Germain property and Saleski prope …
  • OncoSec Medical Inc (ONCS):企業の財務・戦略的SWOT分析
    Summary OncoSec Medical Inc (OncoSec) is a biotechnology company. The company offers services to stimulate body’s immune system and attack cancer. Its lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor th …
  • Bourbon SA (GBB):企業の戦略的SWOT分析
    Bourbon SA (GBB) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Zhejiang Jianfeng Group Company Ltd (600668):製薬・医療:M&Aディール及び事業提携情報
    Summary Zhejiang Jianfeng Group Company Ltd (Jianfeng) is a diversified company. The company operates in the business of manufacturing cement, pharmaceuticals, health products, telecommunication and cables. It offers cement products that includes composite, ordinary, and slag Portland cement product …
  • JX Nippon Oil & Gas Exploration Corp Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    JX Nippon Oil & Gas Exploration Corp Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary JX Nippon Oil & Gas Exploration Corp Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that o …
  • ConMed Corp (CNMD):企業の財務・戦略的SWOT分析
    ConMed Corp (CNMD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Maersk Line AS:企業の戦略的SWOT分析
    Maersk Line AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Andersen Construction Co:企業の戦略的SWOT分析
    Andersen Construction Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Immunovia AB (IMMNOV):製薬・医療:M&Aディール及び事業提携情報
    Summary Immunovia AB (Immunovia) is a molecular diagnostics company that offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis, which can be used in the early diagnosis of cancer, predicting disease …
  • Omron Healthcare Co Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Omron Healthcare Co Ltd (Omron Healthcare), a subsidiary of Omron Corp, is a provider of medical equipment for health monitoring and therapy. The company offers blood pressure monitors, digital thermometers, body fat meters, pedometers, nebulizers, body composition monitors and electric toot …
  • The McClatchy Company (MNI):企業の財務・戦略的SWOT分析
    The McClatchy Company (MNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Biogen Inc (BIIB):企業の財務・戦略的SWOT分析
    Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Smiths Group Plc (SMIN):医療機器:M&Aディール及び事業提携情報
    Summary Smiths Group Plc (Smiths Group) is a diversified technology company. It offers critical solutions for energy and process industries, medical devices and consumables, devices for detection and identification of security threats and contraband, solutions for high speed connectivity and compone …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆